DK1476468T3 - Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet - Google Patents
Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitetInfo
- Publication number
- DK1476468T3 DK1476468T3 DK03705004T DK03705004T DK1476468T3 DK 1476468 T3 DK1476468 T3 DK 1476468T3 DK 03705004 T DK03705004 T DK 03705004T DK 03705004 T DK03705004 T DK 03705004T DK 1476468 T3 DK1476468 T3 DK 1476468T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycoprotein
- directed against
- neutralizing activity
- monoclonal antibody
- human monoclonal
- Prior art date
Links
- 102000003886 Glycoproteins Human genes 0.000 title abstract 2
- 108090000288 Glycoproteins Proteins 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 title 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 title 1
- 238000000338 in vitro Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2002RM000049A ITRM20020049A1 (it) | 2002-01-30 | 2002-01-30 | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
| PCT/IT2003/000032 WO2003064473A2 (en) | 2002-01-30 | 2003-01-29 | Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1476468T3 true DK1476468T3 (da) | 2009-01-19 |
Family
ID=11456013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK03705004T DK1476468T3 (da) | 2002-01-30 | 2003-01-29 | Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050084845A1 (it) |
| EP (1) | EP1476468B9 (it) |
| JP (1) | JP4287280B2 (it) |
| KR (1) | KR101002791B1 (it) |
| CN (1) | CN1856508A (it) |
| AT (1) | ATE407147T1 (it) |
| AU (1) | AU2003208000B2 (it) |
| CA (1) | CA2474801C (it) |
| DE (1) | DE60323333D1 (it) |
| DK (1) | DK1476468T3 (it) |
| EA (1) | EA009861B1 (it) |
| ES (1) | ES2314179T3 (it) |
| IT (1) | ITRM20020049A1 (it) |
| NZ (1) | NZ534922A (it) |
| RU (1) | RU2004126238A (it) |
| WO (1) | WO2003064473A2 (it) |
| ZA (1) | ZA200406187B (it) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7727962B2 (en) | 2004-05-10 | 2010-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Powder comprising new compositions of oligosaccharides and methods for their preparation |
| US7611709B2 (en) * | 2004-05-10 | 2009-11-03 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives |
| US7723306B2 (en) | 2004-05-10 | 2010-05-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation |
| ITTO20070066A1 (it) | 2007-01-30 | 2008-07-31 | Pomona Biotechnologies Llc | Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv |
| WO2008107187A1 (en) * | 2007-03-06 | 2008-09-12 | Ribovax Biotechnologies S.A. | Antibodies specific for rubella virus |
| CN101809033A (zh) | 2007-07-25 | 2010-08-18 | 日本国立感染症研究所 | 对丙型肝炎病毒(hcv)感染具有抑制活性的抗体和其用途 |
| TW200940090A (en) * | 2007-12-17 | 2009-10-01 | Medical Res Council Technology | Hepatitis C virus antibodies |
| ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
| ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
| WO2010035292A1 (en) * | 2008-09-24 | 2010-04-01 | Natimab Therapeutics S.R.L. | The use of a human monoclonal anti-hcv antibody as a medicament for the therapeutic treatment and prevention of hcv infections |
| US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
| ITTO20080964A1 (it) * | 2008-12-22 | 2010-06-23 | Natimab Therapeutics S R L | Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv |
| IT1395961B1 (it) | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv) |
| CN102596996B (zh) | 2009-10-30 | 2014-06-18 | 东丽株式会社 | 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途 |
| US9719141B2 (en) | 2010-03-01 | 2017-08-01 | Vincent Agnello | Prognostic marker for cryoglobulinemic vasculitis and B cell malignancies in HCV infected patients |
| CN104119436B (zh) * | 2013-04-27 | 2016-12-28 | 中国科学院上海生命科学研究院 | 抗丙型肝炎病毒的中和性全人单克隆抗体 |
| GB201415714D0 (en) * | 2014-09-05 | 2014-10-22 | Medical Res Council | Antibodies and antigen binding fragments thereof |
| CN105254756B (zh) * | 2015-11-27 | 2018-09-07 | 武汉大学 | 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用 |
| KR20180001380U (ko) | 2016-10-31 | 2018-05-10 | 대우조선해양 주식회사 | 해양구조물의 발로 작동시키는 캡스탄 |
| CN118440202A (zh) | 2019-12-27 | 2024-08-06 | 凯奥目生物科学株式会社 | 抗cdcp1抗体 |
| WO2022049867A1 (ja) | 2020-09-02 | 2022-03-10 | 国立大学法人東京大学 | がん免疫微小環境の調節物質およびそれによる予防・診断・治療的利用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1325517C (zh) * | 1998-07-21 | 2007-07-11 | 展马博联合股份有限公司 | 抗丙型肝炎病毒抗体及其用途 |
| US7091324B2 (en) * | 1998-11-05 | 2006-08-15 | Board Of Trustees Of Leland Stanford Junior University | Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes |
| AU2001273363A1 (en) | 2000-07-12 | 2002-01-21 | General Instrument Corporation | Method and apparatus for downloading objects via an inband channel with minimal subscriber impact |
| JP2004524829A (ja) * | 2000-12-01 | 2004-08-19 | アメリカ合衆国 | Ｃ型肝炎ウイルスのｅ２糖タンパク質に特異的なモノクローナル抗体、ならびにｃ型肝炎の診断、治療、および予防におけるそれらの使用 |
-
2002
- 2002-01-30 IT IT2002RM000049A patent/ITRM20020049A1/it unknown
-
2003
- 2003-01-29 AU AU2003208000A patent/AU2003208000B2/en not_active Ceased
- 2003-01-29 AT AT03705004T patent/ATE407147T1/de not_active IP Right Cessation
- 2003-01-29 JP JP2003564093A patent/JP4287280B2/ja not_active Expired - Fee Related
- 2003-01-29 RU RU2004126238/13A patent/RU2004126238A/ru not_active Application Discontinuation
- 2003-01-29 EA EA200401081A patent/EA009861B1/ru not_active IP Right Cessation
- 2003-01-29 DK DK03705004T patent/DK1476468T3/da active
- 2003-01-29 DE DE60323333T patent/DE60323333D1/de not_active Expired - Lifetime
- 2003-01-29 EP EP03705004A patent/EP1476468B9/en not_active Expired - Lifetime
- 2003-01-29 NZ NZ534922A patent/NZ534922A/en not_active IP Right Cessation
- 2003-01-29 CA CA2474801A patent/CA2474801C/en not_active Expired - Lifetime
- 2003-01-29 ES ES03705004T patent/ES2314179T3/es not_active Expired - Lifetime
- 2003-01-29 US US10/502,307 patent/US20050084845A1/en not_active Abandoned
- 2003-01-29 KR KR1020047011208A patent/KR101002791B1/ko active IP Right Grant
- 2003-01-29 WO PCT/IT2003/000032 patent/WO2003064473A2/en active IP Right Grant
- 2003-01-29 CN CNA038030926A patent/CN1856508A/zh active Pending
-
2004
- 2004-08-03 ZA ZA200406187A patent/ZA200406187B/en unknown
-
2008
- 2008-05-28 US US12/128,344 patent/US7727529B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2474801A1 (en) | 2003-08-07 |
| RU2004126238A (ru) | 2005-04-20 |
| ATE407147T1 (de) | 2008-09-15 |
| US7727529B2 (en) | 2010-06-01 |
| KR101002791B1 (ko) | 2010-12-21 |
| EA200401081A1 (ru) | 2005-10-27 |
| AU2003208000B2 (en) | 2010-05-20 |
| EA009861B1 (ru) | 2008-04-28 |
| ES2314179T3 (es) | 2009-03-16 |
| CN1856508A (zh) | 2006-11-01 |
| EP1476468B1 (en) | 2008-09-03 |
| WO2003064473A2 (en) | 2003-08-07 |
| JP4287280B2 (ja) | 2009-07-01 |
| ITRM20020049A0 (it) | 2002-01-30 |
| KR20040077745A (ko) | 2004-09-06 |
| EP1476468A2 (en) | 2004-11-17 |
| DE60323333D1 (de) | 2008-10-16 |
| CA2474801C (en) | 2012-03-20 |
| US20050084845A1 (en) | 2005-04-21 |
| NZ534922A (en) | 2008-07-31 |
| EP1476468B9 (en) | 2009-04-08 |
| ITRM20020049A1 (it) | 2003-07-30 |
| ZA200406187B (en) | 2006-06-28 |
| WO2003064473A3 (en) | 2003-12-24 |
| JP2005531286A (ja) | 2005-10-20 |
| US20080241162A1 (en) | 2008-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1476468T3 (da) | Fab-fragmenter af humant monoklonalt antistof rettet mod HCV E2-glycoprotein og med in vitro-neutraliserende aktivitet | |
| DK1534335T3 (da) | FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf | |
| LTC1620113I2 (lt) | Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui | |
| DK1572946T3 (da) | Terapeutisk humant monoklonalt anti-IL-1R1-antistof | |
| MXPA05010830A (es) | Metodos de tratamiento que usan agentes de enlace especificos de angiopoyetina-2 humana. | |
| TR201900764T4 (tr) | LAG-3 ve terapötik antikorlar içeren bileşimler ve bunların kanser tedavisinde kullanımı. | |
| CR8698A (es) | Anticuerpos monoclonales al factor de crecimiento de hepatocito | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| UA90457C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms | |
| ECSP066379A (es) | Anticuerpos rg1 y usos de los mismos | |
| BRPI0513959A (pt) | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos | |
| MX2010004482A (es) | Anticuerpos anti-proteina g vsr. | |
| CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| DK1434791T3 (da) | Specifikke bindingsmidler til human angiopoietin-2 | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| WO2005120557A3 (en) | Inhibition of macrophage-stimulating protein receptor (ron) | |
| AU2001235006A1 (en) | Prophylactic and therapeutic monoclonal antibodies | |
| DK2126049T3 (da) | Antistoffer mod humant cytomegalovirus (hCMV) | |
| WO2001068708A3 (en) | Human and humanized fap-alpha-specific antibodies | |
| UA94211C2 (ru) | Выделенное полностью человеческое моноклональное cd3 антитело | |
| WO2006137938A3 (en) | Antibody fragments for protection from pathogen infection and methods of use thereof | |
| YU55203A (sh) | Konjugati jedinjenja specifičnog makrolida imunske ćelije sa anti-inflamatornim jedinjenjima, za poboljšano ćelijsko ciljanje u anti-inflamatornoj terapiji | |
| EE05474B1 (et) | Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nhtud vhivastaseks vaktsineerimiseks | |
| YU68602A (sh) | Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje | |
| DK1869185T3 (da) | Konjugat med P21-protein til kræftbehandling |